Viridian Therapeutics, Inc.\DE vs vTv Therapeutics
VRDN and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VRDN and VTVT compare
Viridian Therapeutics, Inc.\DE is the larger company, worth 50 times as much as vTv Therapeutics ($3.4B against $68.4M).
vTv Therapeutics grew revenue faster over the last twelve months (216600% versus 23220% for Viridian Therapeutics, Inc.\DE).
vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −544% at Viridian Therapeutics, Inc.\DE.
vTv Therapeutics scores higher on the StockData Score (11 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VRDN | VTVT |
|---|---|---|
| Size and price | ||
| Market cap | $3.4B | $68.4M |
| Share price | $30.06 | $17.29 |
| Change, 1 year | 4.5% | −43.9% |
| Change, 5 years | 64.3% | −67.7% |
| Beta (5Y) | −0.13 | 0.08 |
| Employees | 252 | 26 |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 47.9× | 1.9× (better) |
| P/B | 5.1× | 0.9× (better) |
| FCF yield | −9.8% | – |
| Fair value | $8.47 | $44.97 |
| Margin of safety | −255% | 61.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 23220% | 216600% (better) |
| Revenue growth, 5Y average | 132% | – |
| Profitability | ||
| Operating margin | −570% | −25.1% (better) |
| Net margin | −544% | −12.9% (better) |
| FCF margin | −471% | – |
| Return on equity | −65.7% | −11.7% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −26.0× | – |
| Current ratio | 16.95 (better) | 12.48 |
| Altman Z-score | 2.65 (better) | 0.71 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −1.7% | – |
| Shareholder yield | −1.7% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 120% | 40.6% |
| Held by insiders | 21.8% | 26.3% |
| Insider net buying, 12 months | $19.6M | – |
| Short interest, % of float | 19.2% | 5.0% |
Go deeper
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
- VTVT stock overview
- VTVT income statement
- VTVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.